RALLIS INDIA LTD. Q2 FY27 Results

Q2 delivered a flat revenue but 17% PAT miss, with margin compression QoQ and elevated inventory. Management framed this as strategic (new product mix, inventory build for rabi). Upside hinges on rabi monsoon recovery and pricing power in H2; downside risk is high if commodity/demand remains soft. Near-term execution risk elevated; medium-term dependent on unforecast-able rainfall.

Analysts pressed hard on inventory levels (Prashant Biyani), margins (Riju, Abhijit Akella), and seeds pricing recovery (Rohit Nagraj, Siddharth Gadekar). Management held its ground—defended inventory as strategic, explained margin compression as mix/timing, acknowledged seed headwinds but framed rabi as recovery opportunity. Tone steady but not fully convincing on near-term catalysts.

Score 6/10. Clear on facts and numbers; transparent on headwinds (rain, pricing pressure). However, forward guidance vague (no FY27 numeric targets); heavy reliance on hypothetical rabi recovery. Hedged significantly on near-term visibility. Mixed. Hit revenue guidance (flat ₹858 Cr as expected) but profit miss significant (₹85 Cr vs ₹102 prior year = -17%). Margin compression defended as strategic but execution gap evident. New product contribution (₹100 Cr annualized) early-stage, not yet proven in profit.

Rallis India's standalone Q2 FY27 (quarter ended September 30, 2026) print was weak on a year-on-year basis — the primary lens here, since the business is explicitly flagged as seasonal and monsoon/cropping-pattern dependent. Revenue from operations was effectively flat at ₹858 Cr versus ₹861 Cr a year ago (-0.3%), while net profit fell 16.7% YoY to ₹85 Cr from ₹102 Cr. The reported decline actually understates the underlying weakness: this quarter carried a ₹14 Cr exceptional gain (profit on sale of flats/freehold land) versus a smaller ₹6 Cr equivalent gain in the year-ago quarter. Stripping both one-offs out and applying each period's own effective tax rate, adjusted PAT works out to roughly ₹75 Cr versus ₹98 Cr a year ago — a ~23.6% adjusted YoY decline, meaningfully worse than the 16.7% reported figure. Sequentially, revenue fell 16.1% and PAT fell 32.0% from Q1 FY27's ₹1,022 Cr / ₹125 Cr, but Q1 (the kharif-season quarter) is seasonally the strongest for an agri-inputs business, so this QoQ drop is a seasonality artifact rather than a trend break and should not be read as fresh weakness.

Margins compressed on both comparisons. Net profit margin (on total income) fell to 9.8% from 11.7% a year ago and 12.1% in Q1 FY27. On an EBITDA basis (revenue less operating costs, adding back depreciation and finance costs), margin fell to roughly 14.7% from ~17.9% YoY and ~18.1% QoQ — compression of 320-340bps either way. The squeeze sits mainly in cost of materials and stock-in-trade purchases, which rose faster than revenue even as the company unwound part of Q1's inventory build. Employee costs (₹69 Cr) also normalized upward from Q1's unusually low ₹52 Cr, which had benefited from a one-time ₹35 Cr reversal of performance-incentive and retiral provisions tied to salary-structure harmonisation — a reversal that did not recur in Q2, flattering the QoQ margin base further.

The stock went into the print at ₹204, up 0.9% over the past month of trading.

SBI Mutual Fund sold a 2% stake (Sept 12) and CFO Bhaskar Swaminathan is set to step down Nov 4, 2026 — two overhangs to track into Q3.

Management's July 2026 guidance had called for FY27 agrochemical industry growth of 6-8% and seeds growth in the mid-to-high single digits, with margins "stable-to-soft" and volume recovery contingent on monsoon quality and limited mid-season pricing power. This quarter's flat revenue and 320-390bps margin compression sit below that growth guidance and at the weak end of the margin call, so the print reads as a miss against management's own framing. It also missed Rallis's own pre-result preview, which had expected revenue of ₹900-950 Cr, PAT of ₹100-110 Cr and EBITDA margin of 17-18% — actuals of ₹858 Cr, ₹85 Cr and ~14.7% landed below every band. No verified third-party consensus estimate specific to this quarter could be confirmed via web search; the Street's pre-result stance was already cautious-to-mixed per our preview (price targets spanning ₹179-369 with a split hold/sell/buy rating mix), and this result gives no reason to resolve that disagreement toward the bullish end.

Rallis India enters the September quarter (Q2) — its seasonally stronger period for agri inputs — with mixed momentum. Q1 FY27 delivered headline growth of 31% in PAT, but that was almost entirely a ₹35 Cr one-off provision write-back; underlying profit was flat. The Street is watching whether Q2 can demonstrate real operational traction, not just accounting relief.

The company's Tata-backed agrichemicals portfolio depends heavily on monsoon timing and intensity. Last year, Q2 FY26 saw excessive rains slash domestic crop care revenue by 3%, and the seeds segment cratered 29% due to supply chain bottlenecks. A crucial question: Has supply normalised, and did the 2026 monsoon cooperate?

A strong print: Revenue in the ₹950–1,000 Cr range with PAT above ₹110 Cr would signal that monsoon conditions held and the domestic crop care portfolio is gaining traction. Export momentum (up 33% last year) maintained into Q2 would add credibility to full-year guidance.

A weak print: Revenue below ₹890 Cr or PAT below ₹95 Cr would replay last year's monsoon-strike narrative. A continued sharp decline in seeds would raise questions about execution on supply and product competitiveness. Margin compression below 16% EBITDA would worry the Street on pricing power.

Rallis has not issued formal FY27 revenue or profit guidance on the Q1 call, so there is no explicit target to measure against. However, management has signalled ambitions for consistent double-digit revenue growth and operating leverage expansion. Q1's flat underlying profitability, despite top-line growth, suggests that margin expansion is not yet materialising. Q2 will be a test: if crop care grows mid-single digits and seeds remain in recovery, the full-year trajectory becomes tight for double-digit bottom-line expansion.